The Chemical Cocktail in Your Hair Relaxer
Chemical testing has identified at least 45 endocrine-disrupting or asthma-associated chemicals in hair relaxer products, spanning 10 chemical classes: phthalates (estrogen mimics), parabens (estrogen mimics), formaldehyde and releasing agents (carcinogens), bisphenol A/BPA (estrogen mimic), cyclosiloxanes D4 and D5 (endocrine disruptors, suspected carcinogens), heavy metals (lead, mercury, arsenic, cadmium), alkylphenols (estrogenic), glycol ethers (reproductive toxicants), UV filters (endocrine disruptors), and synthetic musks (estrogenic).
The Scalp Absorption Pathway
Hair relaxers work by applying strong alkaline chemicals (sodium hydroxide or calcium hydroxide) to break protein bonds in hair. These same chemicals damage the scalp's protective barrier — the stratum corneum — dramatically increasing percutaneous absorption of co-formulated EDCs. The burning sensation nearly all users experience confirms active barrier compromise. This broken-barrier pathway delivers chemicals directly into the bloodstream at far higher rates than intact-skin application.
The Labeling Failure
Testing found that 84% of EDCs detected in hair products were NOT disclosed on product labels. Consumers had no way to know what chemicals they were absorbing. Products marketed to children ("Just for Me") contained the same undisclosed EDCs. The labeling gap is central to the failure-to-warn claims.
Reducing Your Exposure
If you currently use chemical hair relaxers, consider transitioning to natural hairstyles, protective styles, or heat-based methods that don't involve chemical application. The Sister Study evidence applies specifically to chemical straightening products, not heat-based tools. Reducing frequency of chemical applications reduces cumulative EDC exposure.
Scientific Evidence
Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study
Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research
View on PubMed→Use of Straighteners and Other Hair Products and Incident Uterine Cancer
Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute
View on PubMed→Use of Hair Products in Relation to Ovarian Cancer Risk
White AJ, Sandler DP, et al. (2021). Carcinogenesis
View on PubMed→Frequently Asked Questions
Related Pages
Hair Relaxer Uterine Cancer
Uterine cancer is the primary injury in the hair relaxer litigation. The NIH Sister Study found a 155% increased risk (HR 2.55) for frequent users. Approximately 67,000 Americans are diagnosed with uterine cancer annually.
Hair Relaxer Ovarian Cancer
The Sister Study found hair relaxer users face a 2.19x increased risk of ovarian cancer. Ovarian cancer is often called the "silent killer" because symptoms are vague until advanced stages, making early detection difficult.
Hair Relaxer Endometriosis
Chemical hair relaxers contain EDCs linked to endometriosis — a painful condition where uterine-like tissue grows outside the uterus. Phthalates and parabens in relaxers promote endometrial implant growth through estrogen mimicry.
Hair Relaxer Settlement Amounts
No hair relaxer cases have settled or gone to trial yet. Attorney estimates project $90,000–$1,000,000+ depending on injury type and severity. Bellwether trials expected in 2027 will establish actual case values.
L'Oréal Hair Relaxer Lawsuit
L'Oréal is the primary defendant in the hair relaxer MDL through its subsidiary SoftSheen-Carson, maker of Dark & Lovely and Optimum Care. L'Oréal is the world's largest beauty company with €38+ billion in annual revenue.
Revlon Dark and Lovely Lawsuit
Revlon is a defendant in the hair relaxer MDL despite filing bankruptcy in 2022. Revlon maintains insurance coverage and allocated ~$44 million for hair relaxer claims in its reorganization plan. Products include Creme of Nature and Revlon Realistic.
Hair Relaxer Lawsuit Black Women
Hair relaxer lawsuits disproportionately affect Black women, who were the primary marketing target, comprise 60% of affected users, and face twice the uterine cancer mortality rate of white women. This is both a product liability and a racial justice case.
Hair Relaxer Cancer Lawsuits Lawsuit
Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.
View full case overview